Cytotoxic Effects of a Triterpene-Enriched Fraction of Cecropia Pachystachya on the Human Hormone-Refractory Prostate Cancer PC3 Cell Line

The analysis of nuclear morphology of PC3 cells treated with triterpene-enriched fraction increased the number of cells with large and regular nuclei suggesting senescence induction, which was supported by β-galactosidase overexpression.
[Biomedicine & Pharmacotherapy]
Cytotoxic effects of a triterpene‐enriched fraction of Cecropia pachystachya on the human hormone-refractory prostate cancer PC3 cell line - ScienceDirect. (n.d.). Retrieved August 11, 2020, from https://www.sciencedirect.com/science/article/pii/S0753332220307447?via%3Dihub Cite
Full Article

Continue reading “Cytotoxic Effects of a Triterpene-Enriched Fraction of Cecropia Pachystachya on the Human Hormone-Refractory Prostate Cancer PC3 Cell Line”

Bookmark

No account yet? Register

0
Share

Secretome Analysis Reveals Upregulated Granzyme B in Human Androgen-Repressed Prostate Cancer Cells with Mesenchymal and Invasive Phenotype

Scientists used proteomics approaches to investigate the secreted proteins of paired human androgen-repressed prostate cancer cell lines, representing the epithelial and mesenchymal phenotypes.
[PLoS One]
Bou-Dargham, M. J., & Sang, Q.-X. A. (2020). Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype. PLOS ONE, 15(8), e0237222. https://doi.org/10.1371/journal.pone.0237222 Cite
Full Article

Continue reading “Secretome Analysis Reveals Upregulated Granzyme B in Human Androgen-Repressed Prostate Cancer Cells with Mesenchymal and Invasive Phenotype”

Bookmark

No account yet? Register

1+
Share

PIM1 Accelerates Prostate Cancer Cell Motility by Phosphorylating Actin Capping Proteins

Researchers identified capping proteins CAPZA1 and CAPZB2 as PIM1 substrates, and showed that phosphorylation of either of them led to increased adhesion and migration of human prostate cancer cells.
[Cell Communication and Signaling]
Santio, N. M., Vainio, V., Hoikkala, T., Mung, K. L., Lång, M., Vahakoski, R., Zdrojewska, J., Coffey, E. T., Kremneva, E., Rainio, E.-M., & Koskinen, P. J. (2020). PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins. Cell Communication and Signaling, 18(1), 121. https://doi.org/10.1186/s12964-020-00618-6 Cite
Full Article

Continue reading “PIM1 Accelerates Prostate Cancer Cell Motility by Phosphorylating Actin Capping Proteins”

Bookmark

No account yet? Register

0
Share

Inhibition of TMPRSS2 by HAI-2 Reduces Prostate Cancer Cell Invasion and Metastasis

Hepatocyte growth factor activator inhibitor-2 overexpression could suppress the induction effect of TMPRSS2 on pro-HGF activation and prostate cancer cell invasion.
[Oncogene]
Ko, C.-J., Hsu, T.-W., Wu, S.-R., Lan, S.-W., Hsiao, T.-F., Lin, H.-Y., Lin, H.-H., Tu, H.-F., Lee, C.-F., Huang, C.-C., Chen, M.-J. M., Hsiao, P.-W., Huang, H.-P., & Lee, M.-S. (2020). Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis. Oncogene, 1–14. https://doi.org/10.1038/s41388-020-01413-w Cite
Full Article

Continue reading “Inhibition of TMPRSS2 by HAI-2 Reduces Prostate Cancer Cell Invasion and Metastasis”

Bookmark

No account yet? Register

0
Share

NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403

Cancer Targeted Technology announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research Phase IIB grant.
[Cancer Targeted Technology (Business Wire, Inc.)]
Press Release

Continue reading “NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403”

Bookmark

No account yet? Register

0
Share

Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review

Researchers review the current status of immunotherapy, including new discoveries and precision approaches to prostate cancer, and discuss future directions in the continuously evolving landscape of immunotherapy.
[International Journal of Molecular Sciences]
Kim, T. J., & Koo, K. C. (2020). Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences, 21(15), 5484. https://doi.org/10.3390/ijms21155484 Cite
Full Article

Continue reading “Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review”

Bookmark

No account yet? Register

0
Share

Chelerythrine Suppresses Proliferation and Metastasis of Human Prostate Cancer Cells via Modulating MMP/TIMP/NF-κB System

The addition of chelerythrine significantly inhibited the proliferation of androgen-independent prostate cancer DU145 and PC-3 cells at the concentration of 5 and 10 μM, but not on androgen-dependent prostate cancer LNCaP cells as well as normal prostate epithelial cell line PrEC cells.
[Molecular and Cellular Biochemistry]
Yang, B., Zhang, D., Qian, J., & Cheng, Y. (2020). Chelerythrine suppresses proliferation and metastasis of human prostate cancer cells via modulating MMP/TIMP/NF-κB system. Molecular and Cellular Biochemistry. https://doi.org/10.1007/s11010-020-03845-0 Cite
Abstract

Continue reading “Chelerythrine Suppresses Proliferation and Metastasis of Human Prostate Cancer Cells via Modulating MMP/TIMP/NF-κB System”

Bookmark

No account yet? Register

0
Share

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

ORIC Pharmaceuticals, Inc. announced it has entered into an exclusive worldwide license agreement with Mirati Therapeutics, Inc. ORIC will have exclusive worldwide rights for the development activities and commercialization of a small molecule allosteric inhibitor program directed towards the polycomb repressive complex 2, a validated oncogenic target across several cancers with promising therapeutic potential in prostate cancer, among other indications.
[ORIC Pharmaceuticals, Inc.]
Press Release

Continue reading “ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics”

Bookmark

No account yet? Register

0
Share

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells

Scientists developed curcumin nanoparticles and evaluated their cytotoxicity in docetaxel (DTX)-resistant castration-resistant prostate cancer (CRPC) cells for the treatment of DTX-resistant CRPC.
[Biomedicines]
Tanaudommongkon, I., Tanaudommongkon, A., Prathipati, P., Nguyen, J. T., Keller, E. T., & Dong, X. (2020). Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells. Biomedicines, 8(8), 253. https://doi.org/10.3390/biomedicines8080253 Cite
Full Article

Continue reading “Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells”

Bookmark

No account yet? Register

0
Share

Predicting New Drug Indications for Prostate Cancer: The Integration of an In Silico Proteochemometric Network Pharmacology Platform with Patient‐Derived Primary Prostate Cells

Researchers integrated a computational proteochemometric systems network pharmacology platform, DrugGenEx‐Net, with primary, continuous cultures of conditionally reprogrammed normal and prostate cancer (PCa) cells derived from treatment‐naive patients with primary PCa.
[Prostate]
Naeem, A., Dakshanamurthy, S., Walthieu, H., Parasido, E., Avantaggiati, M., Tricoli, L., Kumar, D., Lee, R. J., Feldman, A., Noon, M. S., Byers, S., Rodriguez, O., & Albanese, C. (n.d.). Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. The Prostate, n/a(n/a). https://doi.org/10.1002/pros.24050 Cite
Full Article

Continue reading “Predicting New Drug Indications for Prostate Cancer: The Integration of an In Silico Proteochemometric Network Pharmacology Platform with Patient‐Derived Primary Prostate Cells”

Bookmark

No account yet? Register

0
Share

Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice

Scientists determined the effects of grape antioxidants quercetin and/or resveratrol against prostate cancer in the transgenic adenocarcinoma of mouse prostate (TRAMP)-model in prevention and intervention settings.
[Cancers]
Singh, C. K., Chhabra, G., Ndiaye, M. A., Siddiqui, I. A., Panackal, J. E., Mintie, C. A., & Ahmad, N. (2020). Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice. Cancers, 12(8), 2141. https://doi.org/10.3390/cancers12082141 Cite
Full Article

Continue reading “Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice”

Bookmark

No account yet? Register

0
Share

The Prostaglandin Synthases, COX-2 and L-PGDS, Mediate Prostate Hyperplasia Induced by Low-Dose Bisphenol A

In vitro studies showed that low-dose bisphenol A promoted the proliferation of human prostate fibroblasts and epithelial cells, and significantly upregulated the expression of cyclooxygenase-2 (COX-2) and L-PGDS in the cells.
[Scientific Reports]
Wu, S., Huang, D., Su, X., Yan, H., Ma, A., Li, L., Wu, J., & Sun, Z. (2020). The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A. Scientific Reports, 10(1), 13108. https://doi.org/10.1038/s41598-020-69809-y Cite
Full Article

Continue reading “The Prostaglandin Synthases, COX-2 and L-PGDS, Mediate Prostate Hyperplasia Induced by Low-Dose Bisphenol A”

Bookmark

No account yet? Register

0
Share
Share